Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several grapefruit-atorvastatin interaction claims are not directly supported by the provided label excerpts, including statements about mechanism specifics (intestinal enzymes), clinical framing (side effects 'greatest concern' from increased levels), guidance (avoid altogether), strength comparisons (strongest/most consistent), and modifiers (individual metabolism differences, smaller amounts, whole grapefruit, or differential effects across statins).
Category Scores
Accurate Statements
Grapefruit juice interferes with how the body breaks down atorvastatin (Lipitor).
7.2 Grapefruit Juice (components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin).
Grapefruit juice can raise atorvastatin (Lipitor) levels in the bloodstream.
7.2 Grapefruit Juice (can increase plasma concentrations of atorvastatin).
The risk from grapefruit juice generally increases with more grapefruit juice or more frequent intake.
7.2 Grapefruit Juice (especially with excessive consumption >1.2 liters/day) and footnote in 12.3/Table 3 indicating greater increases with excessive grapefruit consumption (≥750 mL–1.2 L/day).
Statin-associated muscle injury can range from mild muscle aches to the rare but serious condition rhabdomyolysis.
5.1 Skeletal Muscle (myopathy defined as muscle aches or weakness; rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria reported with LIPITOR and other drugs in class).
Unsupported Statements
Grapefruit juice affects intestinal enzymes involved in drug metabolism for atorvastatin.
The provided label excerpt for grapefruit specifically describes CYP 3A4 inhibition; it does not state that grapefruit acts via intestinal enzymes.
Higher atorvastatin blood levels increase the risk of atorvastatin side effects.
The provided label excerpts discuss increased plasma concentrations with grapefruit and myopathy/rhabdomyolysis risk with certain interacting agents/higher doses, but do not explicitly link grapefruit-related higher plasma levels to increased side-effect risk broadly.
The side effects of greatest concern with increased atorvastatin levels are muscle-related problems.
While the label highlights skeletal muscle (myopathy/rhabdomyolysis) in warnings, the provided excerpts do not frame this as 'greatest concern' specifically from increased atorvastatin levels due to grapefruit.
Higher atorvastatin exposure than intended is associated with increased concern for statin-associated muscle injury.
The provided label discusses increased risk of myopathy/rhabdomyolysis with certain interacting drugs and with higher doses, but it does not explicitly state 'higher exposure than intended' as a grapefruit-related concept.
The risk from grapefruit juice is influenced by individual differences in metabolism and by other medications a person may be taking.
The provided grapefruit excerpt does not mention individual metabolism differences; other medications are discussed for myopathy risk generally, but not specifically framed as influencing grapefruit-risk via individual metabolism.
Even smaller amounts of grapefruit juice can be enough to matter for some people.
The provided label excerpts emphasize 'excessive' consumption (>1.2 L/day) and report increased AUC/Cmax with a specific measured dose (e.g., 240 mL QD), but they do not state that 'even smaller amounts' can matter for some people.
Common guidance is to avoid grapefruit juice altogether with Lipitor (atorvastatin).
The provided label excerpt (7.2) does not instruct avoidance 'altogether.' It describes increased risk especially with excessive consumption.
The concern is strongest with grapefruit juice because it has a higher concentration and more consistent effect on the enzymes that affect drug levels.
The provided label excerpt does not compare relative strength across interactions or attribute 'strongest' concern to concentration/consistency of enzyme effects.
Whole grapefruit may still contain the compounds involved in the interaction, but juice is the most common trigger for drug-interaction warnings.
The provided label excerpt addresses 'Grapefruit Juice' specifically and does not address whole grapefruit or assert that juice is the most common trigger.
Not all statins are affected similarly by grapefruit.
The provided label excerpts discuss LIPITOR/atorvastatin and class-level myopathy risk but do not compare grapefruit effects across statins.
The grapefruit interaction is most well known with certain statins, including atorvastatin.
The provided label excerpts do not include comparative statements about which statins have the best-known grapefruit interaction.
Contradictions
Important Omissions
The label excerpt specifies that grapefruit juice contains components that inhibit CYP 3A4 and increase atorvastatin plasma concentrations, especially with excessive consumption (>1.2 liters/day). Some response claims implied broader/stronger guidance (avoid altogether) without retaining the label’s 'especially with excessive consumption' phrasing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements overgeneralize beyond the provided label (e.g., 'avoid altogether,' 'greatest concern,' and mechanistic strength/modifiers). These could lead to inaccurate patient understanding of the interaction risk magnitude or thresholds relative to what the provided label excerpts support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple grapefruit-related claims are not supported by the provided label excerpts, including specific guidance and comparative/individual variability/mechanistic details.
Suggested Improvement
Constrain grapefruit interaction statements to the provided label language: CYP 3A4 inhibition and increased atorvastatin plasma concentrations, particularly with excessive grapefruit juice consumption (>1.2 L/day), and avoid adding unlabeled thresholds, 'avoid altogether' guidance, and comparative claims about other statins or relative strength.